Amox clav 400

Clarithromycin-containing regimens are associated with a high eradication rate and less side effects than regimens that include metronidazole. 1,000 mg PO twice daily with clarithromycin (500 mg PO twice daily) and omeprazole (20 mg twice daily) for 10 to 14 days.

For patients with an active ulcer, an additional 14 days of omeprazole (20 mg once daily) is recommended for ulcer healing.

According to ACG, any standard dose PPI may be substituted for omeprazole in this regimen.

More effective triple drug regimens are available and recommended. The original FDA-approved dual regimen consists of amoxicillin 1,000 mg PO and lansoprazole (30 mg PO), each given three times daily for 14 days.

Clinical trials showed eradication rates of about 70%, which is substantially lower than that achieved with triple-drug therapy regimens; triple-drug therapy was shown to be more effective than all possible dual therapy combinations. 1,000 mg PO twice daily with metronidazole (500 mg PO twice daily) and omeprazole (20 mg twice daily) for 10 to 14 days. For patients with an active ulcer, an additional 14 days of omeprazole (20 mg once daily) is recommended for ulcer healing.

According to ACG, any standard dose PPI may be substituted for omeprazole in this regimen. A prospective, open label study evaluated the effectiveness of levofloxacin-based dual (levofloxacin/rabeprazole) and triple (levofloxacin/amoxicillin/rabeprazole) therapy in eradicating H.

Patients (n = 160) were randomized into 4 groups (3 dual and 1 triple therapy regimen).

The dual regimens consisted of levofloxacin 500 mg PO once daily with rabeprazole (20 mg PO once daily) for 5, 7, or 10 days. The triple regimen included amoxicillin 1,000 mg PO twice daily, levofloxacin (500 mg once daily), and rabeprazole (20 mg once daily) for 7 days. Triple therapy resulted in a significantly higher eradication rate (more than 90%) than dual therapy at any duration (70% or less). 25 mg/kg/dose PO twice daily (Max: 1 g/dose) with metronidazole (10 mg/kg/dose PO twice daily [Max: 500 mg/dose]) and a proton pump inhibitor (PPI; 1 to 2 mg/kg/day PO divided every 12 hours [Max: 20 mg/dose]) for 1 to 2 weeks.

25 mg/kg/dose PO twice daily (Max: 1 g/dose) with clarithromycin (10 mg/kg/dose PO twice daily [Max: 500 mg/dose]) and a proton pump inhibitor (PPI; 1 to 2 mg/kg/day PO divided every 12 hours [Max: 20 mg/dose]) for 1 to 2 weeks.

25 mg/kg/dose PO twice daily (Max: 1 g/dose) with a proton pump inhibitor (PPI; 1 to 2 mg/kg/day PO divided every 12 hours [Max: 20 mg/dose]) for 5 days, followed-up by a PPI plus clarithromycin (10 mg/kg/dose PO twice daily [Max: 500 mg/dose]) and metronidazole (10

mg/kg/dose

Treat for 7 to 10 days for naturally acquired infection. For a bioterrorism-related event, treat for a total duration of 60 days. Following initial treatment for severe anthrax infection, amoxicillin as a single agent may also be used as follow-up treatment.

75 mg/kg/day PO divided every 8 hours (Max: 1 g/dose) as an alternative for penicillin-susceptible strains. Treat for 7 to 10 days for naturally acquired infection. For a bioterrorism-related event, continue treatment for 60 days.

As oral follow-up combination therapy after initial IV therapy for severe anthrax (non-CNS infection), use amoxicillin in combination with a protein synthesis inhibitor (i.e., clindamycin, doxycycline, linezolid). Continue therapy to complete a treatment course of at least 14 days; additional prophylaxis to complete an antimicrobial course of up to 60 days may be required.

75 mg/kg/day PO divided every 8 hours as an alternative for penicillin-susceptible strains.

Treat for 7 to 10 days for naturally acquired infection.

For a bioterrorism-related event, continue treatment for 60 days.

As oral follow-up combination therapy after initial IV therapy for severe anthrax (non-CNS infection), use amoxicillin in combination with a protein synthesis inhibitor (i.e., clindamycin, linezolid). Continue therapy to complete a treatment course of at least 14 days; additional prophylaxis to complete an antimicrobial course of up to 60 days may be required. 50 mg/kg/day PO divided every 12 hours as an alternative for penicillin-susceptible strains. Treat for 7 to 10 days for naturally acquired infection.

For a bioterrorism-related event, continue treatment for 60 days.

As oral follow-up combination therapy after initial IV therapy for severe anthrax (non-CNS infection), use amoxicillin in combination with a protein synthesis inhibitor (i.e., clindamycin, linezolid). Continue therapy to complete a treatment course of at least 14 days; additional prophylaxis to complete an antimicrobial course of up to 60 days may be required.

1 g PO every 8 hours for 60 days after exposure as an alternative for penicillin-susceptible strains for patients who cannot take first-line agents (i.e., fluoroquinolones, doxycycline) or if first-line agents are unavailable.

75 mg/kg/day PO divided every 8 hours (Max: 1 g/dose) for 60 days after exposure for penicillin-susceptible strains. 75 mg/kg/day PO divided every 8 hours for 60 days after exposure for penicillin-susceptible strains. 50 mg/kg/day PO divided every 12 hours for 60 days after exposure for penicillin-susceptible strains. 250 mg PO every 8 hours in combination with oral erythromycin for 5 days, following 48 hours of IV therapy. A 7-day course of therapy with broad-spectrum

antibiotics

Administration of broad-spectrum antibiotics has been shown to prolong pregnancy, reduce maternal and neonatal infections, and reduce gestational age-dependent morbidity. Women with preterm PROM who are candidates for group B streptococcal (GBS) intrapartum prophylaxis should receive GBS prophylaxis to prevent vertical transmission regardless of earlier treatments.[64408] †Indicates off-label use.

1,750 mg/day PO for most labeled indications; however, doses up to 3 g/day PO have been used off-label. 1,750 mg/day PO for most labeled indications; however, doses up to 3 g/day PO

have

1,750 mg/day PO is FDA-approved maximum; however, doses up to 4 g/day PO have been used off-label. 45 mg/kg/day PO is FDA-approved maximum; however, doses up to 100 mg/kg/day PO (Max: 4 g/day) have been used off-label. 4 to 11 months: 45 mg/kg/day PO is FDA-approved maximum; however, doses up to 90 mg/kg/day PO have been used off-label. 1 to 3 months: 30 mg/kg/day PO is FDA-approved maximum; however, doses up to 75 mg/kg/day PO have been used off-label. 30 mg/kg/day PO is FDA-approved maximum; however, doses up to 75 mg/kg/day PO have been used off-label. No dosage adjustment needed; amoxicillin is not appreciably metabolized in the liver and does not undergo biliary secretion. The following dosing recommendations pertain to adults.

No specific dosage adjustments for pediatric patients with renal impairment are available at this time; however, dosage intervals should be adjusted.

CrCl 10—30 mL/min: 250—500 mg PO every 12 hours, depending on the severity of the infection. Do not use the 875 mg-tablet strength or the extended-release tablet for dosing. CrCl 3 months of age because of incompletely developed renal function. Safety and effectiveness of Moxatag extended-release tablets has not been established in neonates, infants, or children.

A service of the National Library of Medicine, National

Institutes

Amoxicillin is one of the most commonly used antibiotics in the primary care setting. It is an amino-penicillin, created by adding an extra amino group to penicillin, to battle antibiotic resistance. Amoxicillin covers a wide variety of gram-positive bacteria, with some added gram-negative coverage compared to penicillin.

Similar to penicillin, it covers most Streptococcus species and has improved coverage of Listeria monocytogenes and Enterococcus .

It also has coverage over Haemophilus influenzae , some Escherichia coli , Actinomyces , Clostridial species, Salmonella , Shigella , and Corynebacteria .

Amoxicillin is FDA approved for the treatment of genitourinary tract infections, ear, nose, and throat infections, lower

respiratory

It is recommended as the first-line treatment by the Infectious Disease Society of America (IDSA), for acute bacterial rhinosinusitis and as one of the treatments for community-acquired pneumonia.[1] For this, it is often in combination with a macrolide antibiotic.